Ricardo Gazzinelli is Professor at the Federal University of Minas Gerais (UFMG), Senior Investigator at the René Rachou Institute from Oswaldo Cruz Foundation (Fiocruz), Professor at the University of Massachusetts Medical School (UMMS), and CNPq Researcher. He has done important contributions in the area of innate immunity and CD8+ T cells in infections with protozoan parasites. He is the Director of the National Institute of Science and Technology in Vaccines/MCT, and has contributed for the development of vacines against neglected diseases, which include Chagas disease, leishmaniasis, and malaria. He is member of the Brazilian National Academy of Sciences, the Third World Academy of Sciences (TWAS), and has been awarded with the following Prizes and Honors: Biotechnology Fellowship from Rockefeller Foundation (1995-1998); Fundep Award, Biomedical Sciences (2002); fellowship from John Simon Guggenheim Memorial Foundation (2004); prêmio CAPES/ELSEVIER; TWAS award, Medical Sciences; Marcos Mares-Guia award, FAPEMIG/SESTEC (2009); Commandeer (2007) and Grand-Croix (2010) from the Ministry of Science and Technology; Grand Award CAPES for Thesis (Supervisor) - Biological Sciences; Chair CAPES/Harvard (2013-2014); Award Santander University, area Biotechnology (2013); Péter Murányi Award, Inovation in Medicine (2014); the Bunge Award for prevention of infectious diseases (2021); and Confap Award, Life Sc iences (2021). Co-founder of the Center of Technology and Vaccines (UFMG-Fiocruz) and Detechta Biotecnologia, S.A. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP-funded startups are developing COVID-19 vaccines |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Our proposal will consist of the evaluation of the mechanisms of the disease in models of pulmonary comorbidities challenged with SARS-CoV-2 and protection induced by a vaccine using a recombinant influenza virus expressing a segment of the Spike protein. We hypothesis is that the pathology triggered by excessive activation of the innate immune response in the airway mucosa and that with …
Respiratory syndromes are associated with lung endothelium damage. Recently, the SARS-CoV-2, the main cause of Coronavirus Disease 19 (Covid-19) was associated with several lung endothelium damages, including alveolar dysfunction. Also, regarding pulmonary injury, immunological response leads to a complex inflammatory response from resident cells into the respiratory tract. The balance be…
| 1 / 1 | Completed research grants |
| 1 / 1 | Completed scholarships in Brazil |
| 2 / 2 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID